glycyl-arginyl-glycyl-aspartyl-seryl-proline has been researched along with etoposide in 1 studies
| Studies (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Trials (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Recent Studies (post-2010) (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Studies (etoposide) | Trials (etoposide) | Recent Studies (post-2010) (etoposide) |
|---|---|---|---|---|---|
| 162 | 1 | 20 | 18,306 | 3,693 | 4,900 |
| Protein | Taxonomy | glycyl-arginyl-glycyl-aspartyl-seryl-proline (IC50) | etoposide (IC50) |
|---|---|---|---|
| nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | 1.153 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 1.4284 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 3.187 | |
| Caspase-3 | Homo sapiens (human) | 1 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 0.4299 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoyt, DG; Johnson, CS; Lazo, JS; Mannix, RJ; Modzelewski, RA; Rusnak, JM | 1 |
1 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-seryl-proline and etoposide
| Article | Year |
|---|---|
Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells.
Topics: Animals; Antibodies; Antigens, CD; Basement Membrane; Cell Adhesion; Cell Survival; Cells, Cultured; DNA Damage; Endothelium, Vascular; Etoposide; Extracellular Matrix Proteins; Fibronectins; Fibrosarcoma; Gelatin; Integrin alpha5; Integrin beta1; Integrin beta3; Integrins; Laminin; Lipopolysaccharides; Mice; Mice, Inbred C3H; Oligopeptides; Platelet Membrane Glycoproteins | 1996 |